The fast transient outward K ؉ current (I to,f ) plays a critical role in early repolarization of the heart.
T he fast transient outward potassium current (I to,f ) is carried by channels comprised of voltage-gated ␣ poreforming subunits (Kv4.3 in humans and Kv4.2 and Kv4.3 in rodents) and auxiliary subunit KChIP2. 1 I to,f modulates the action potential profile, Ca 2ϩ handling, contractility, and hypertrophy 2,3 in cardiac myocytes, and regional differences in I to,f contribute to the transmural ventricular electric heterogeneity. 4 -6 Heart disease is invariably associated with reductions in I to,f , 1 whereas changes in I to,f have been linked to Brugada syndrome arrhythmias. 7 Despite the importance of I to,f in normal and diseased hearts, the underlying mechanisms for its regulation are poorly understood. Previous studies have established that activation of receptors, such as angiotensin II and ␣ 1 -adrenergic (␣ 1 -AR), reduces I to,f and the expression of its molecular constituents. 1 Although I to,f changes induced by chronic ␣ 1 -AR stimulation have been linked to activation of calcineurin and its downstream transcriptional factor, NFAT (nuclear factor of activated T cells), 8 calcineurin-NFAT activation can either increase 9 or decrease 8 I to,f levels, suggesting that this pathway is not the primary regulator of I to,f . Thus, the search continues for the molecular regulators of I to,f . In this regard, the ubiquitous transcription factor nuclear factor (NF)-B is also activated by chronic ␣ 1 -AR stimulation 10 and in heart disease patients. 11 NF-B is particularly intriguing because it is involved in hypertrophic growth of cultured cardiomyocytes 12, 13 and in animal models. 14, 15 Moreover, the inflam-matory cytokine tumor necrosis factor (TNF)␣, the classic NF-B activator, also reduces I to,f . 12 Therefore, we investigated the regulation of I to,f by NF-B in cultured neonatal rat ventricular myocytes (NRVMs). We found that NF-B mediates ␣ 1 -AR-induced reductions in I to,f , by repressing KChIP2 expression.
Methods
NRVMs were isolated and cultured as described previously. 9 Adenoviral transfections and drug treatments were performed 24 hours after isolation with electrophysiological and mRNA measurements made 40 hours thereafter.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
Consistent with previous studies, 16 Figure 1 shows that activation of ␣ 1 -ARs with phenylephrine (PE) plus propranolol (Pro) (a ␤-AR antagonist) reduced (PϽ0.01) I to,f densities from 16.8Ϯ1.9 pA/pF in control (CTRL) to 5.8Ϯ1.9 pA/pF and increased (PϽ0.05) cell capacitance (indicating hypertrophy 16 ) (see Online Figure II ). PE/Pro also decreased (PϽ0.01) KChIP2 and Kv4.3 by Ϸ50%, while increasing (PϽ0.05) Kv4.2 mRNA ( Figure 1 ) and protein (Online Figure III ) compared with CTRL. The Kv4.2 increases with ␣ 1 -AR stimulation contrasts with previous studies 9, 16 and can be readily explained by the observation that PE coactivates ␣ 1 -and ␤-ARs 17 when ␤-AR blockers are absent. Consistent with this idea, PE alone did not cause an increase in Kv4.2 expression ( Figure 2 ). To better clarify the effects ␤-AR stimulation on I to,f genes, we also treated myocytes with isoproterenol (Iso) which caused decreases in mRNA expression of all three genes, with Kv4.2 expression being the most severely effected ( Figure 2 ). These results are consistent with the conclusion that selective ␣ 1 -AR stimulation upregulates Kv4.2 expression, whereas ␤-AR stimulation alone downregulates Kv4.2 expression. However, it is nevertheless conceivable that some of the effects of PE/Pro were mediated by effects of Pro. We found that Pro alone had not effect KChIP2 and Kv4.3 levels, while moderately decreasing Kv4.2 expression. The decreases in Kv4.2 expression may be explained by the paradoxical effects reported previously showing that Pro (and other ␤-AR blockers) can exert inverse agonism effects leading to activation of extracellular signal-regulated kinase (ERK) (see Discussion). 18 On the other hand, the ␣ 1 -AR blocker prazosin (Pz) prevented both reductions in KChIP2 and Kv4.3 as well as the increases in Kv4.2 expression caused by PE/Pro ( Figure 2 ). Thus, changes in expression of I to,f gene expression observed with PE/Pro can be attributed to consequences of selective ␣ 1 -AR stimulation.
To assess the involvement of NF-B in ␣ 1 -AR-mediated I to,f reductions, NRVMs were infected (using adenoviruses) expressing a phosphorylation-deficient mutant of IB␣ (IkB␣SA) capable of preventing NF-B nuclear translocation. 19 Control experiments used myocytes expressing green fluorescent protein (GFP) alone. Figure 3 shows that IB␣SA prevented the ␣ 1 -AR-mediated reductions in I to,f and KChIP2 expression without affecting Kv4.2 and Kv4.3 levels. A 2-way ANOVA analysis of the I to,f and KChIP2 data revealed interactions (PϽ0.001) between PE/Pro and IB␣SA, establishing that the ␣-ARinduced reductions are mediated through canonical NF-B signaling. This is further supported by data in Figure 4 showing that PE/Pro directly increases NF-B transcriptional activity (PϽ0.01). Because the canonical NF-B pathway leads to the nuclear translocation of NF-B dimers through the activation of an IKK␣-IKK␤ complex, which targets the IB protein for proteasome-mediated degradation, we overexpressed IB kinase (IKK)␤ to directly activate NF-B transcriptional activity. 20 As with PE/Pro, overexpression of IKK␤ also decreased (PϽ0.01) I to,f and KChIP2, while increasing (PϽ0.001) Kv4.2 but without affecting Kv4.3 levels ( Figure 5 ). Moreover, inhibition of NF-B with IB␣SA overexpression alone nearly doubled (PϽ0.001) KChIP2 while slightly decreasing Kv4.2 (versus GFP) without affecting Kv4.3 mRNA ( Figure 3 ). The inability of IB␣SA to increase I to,f despite increasing KChIP2, suggests that Kv4.2 expression levels limit the number of functional I to,f channels under our experimental conditions (see Discussion). Because TNF␣ both activates the canonical NF-B signaling pathway and reduces I to,f , NRVMs were chronically treated with TNF␣. Figure 6 shows that TNF␣ reduced I to,f and KChIP2 and Kv4.3 expression, whereas Kv4.2 was unchanged. Furthermore, IB␣SA prevented the TNF␣-mediated reductions in I to,f and KChIP2 (but not Kv4.3) expression while further decreasing Kv4.2 mRNA (PϽ0.05) (which suggests that TNF␣ has a negative effect on Kv4.2 in the absence of NF-B activation). Importantly, 2-way ANOVA analysis of the I to,f and KChIP2 data established an interaction (PϽ0.001) between the TNF␣ and the IB␣SA, further supporting the conclusion that NF-B mediates I to,f reductions by decreasing KChIP2 levels.
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Although our data strongly implicate NF-B in the downregulation of I to,f through control of KChIP2 expression, we investigated the potential role of calcineurin in mediating some of the observed effects. Unlike the NF-B inhibitor, the calcineurin inhibitor CAIN 21 significantly reduced the expression of KChIP2 under basal conditions ( Figure 7 ) and failed to prevent any ␣ 1 -AR-mediated reductions in KChIP2 expression. CAIN also decreased (PϽ0.05) Kv4.2 expression both in the presence and absence of PE/Pro, consistent with the conclusion that calcineurin is a positive regulator of Kv4.2 expression. 9 Kv4.3 expression was unchanged by CAIN. Despite these complex effects of CAIN, a 2-way ANOVA analysis showed no significant interaction (PϾ0.05) between PE/Pro and CAIN.
Discussion
The transcriptional mechanisms underlying the I to,f reductions seen in heart disease are poorly understood. Here, we show that chronic ␣-AR activation (with PE/Pro), which occurs with cardiac hypertrophy and disease, 9, 16 decreases I to,f in association with KChIP2 and Kv4.3 subunit mRNA reductions and Kv4.2 elevations. These I to,f reductions, despite increases in Kv4.2 expression, suggest that KChIP2 and/or Kv4.3 subunits are limiting factors for I to,f channel production when ␣-ARs are stimulated, consistent with the requirement for KChIP2 subunits 22 and Kv4.3 subunits 1 for I to,f channel assembly in cardiomyocytes.
Involvement of NF-B in reductions of I to,f by PE/Pro is supported by our results showing that PE/Pro increases in NF-B activity (Figure 4 ) and that the reductions in I to,f induced by ␣-AR stimulation could be prevented with NF-B inhibition (Figure 3 ). The molecular basis for the NF-Bmediated reductions in I to,f (by either ␣-AR or TNF␣ stimulation) are complex and illustrated graphically in Figure 8 . Our data strongly support the conclusion that NF-B-mediated I to,f reductions arise primarily from decreased KChIP2 levels, which then limits I to,f channel assembly for several reasons. First, NF-B inhibition leads to KChIP2 elevations both in the presence and absence of ␣-AR stimulation, while having minimal effects on Kv4.2/3 subunits. Second, activation of canonical NF-B signaling (with IKK␤) reduced KChIP2 and I to,f , despite increasing Kv4.2 expression without affecting Kv4.3 expression. Additionally, the I to,f reductions observed with PE/Pro and TNF␣ treatments, as well as with IKK␤ correlated with changes in KChIP2, but not Kv4.3 or Kv4.2 expression levels. Interestingly, when NF-B is inhibited in the absence of PE/Pro, the KChIP2 increases (above baseline) are not accompanied by I to,f elevations. Although this observation may seem at odds with our conclusion that NF-B activation reduces I to,f by decreasing KChIP2 expression, it can be readily explained if other subunits become the limiting factors in I to,f channel production when KChIP2 levels are increased. Consistent with this explanation, when NF-B is inhibited with IB␣SA, Kv4.2 expression is slightly reduced. This mechanism (ie, Kv4.2 subunits limiting channel production) is also consistent with previous studies showing that changes in Kv4.2 are responsible for changes in I to,f and that I to,f channel production can be limited by Kv4.2 levels. [23] [24] [25] For example, we previously showed that Kv4.2 expression strongly correlates with I to,f different regions of the rat heart. 24 On the other hand, it was recently reported by Jin et al 25 that overexpression of KChIP2 increases I to,f , in conjunction with elevations in Kv4.2 levels, 25 which contrasts with decreases in Kv4.2 expression seen when KChIP2 increased with NF-B inhibition. Thus, although the changes in KChIP2 expression, as seen with alterations in NF-B activity, can clearly affect Kv4.2 expression, it seems unreasonable to suppose that NF-B's actions on Kv4.2 expression are mediated exclusively through changes in KChIP2. Regardless, the differences between our studies and those of Jin et al 25 can be readily explained by experimental differences (ie, viral overexpression of KChIP2 versus changes in KChIP2 via altered NF-B signaling). In addition, it is important to keep in mind that although our conclusions are strongly supported by our current and mRNA data, we did not analyze KChIP2 and Kv4.3 protein levels. Thus, we cannot exclude the possibility that some of the observed effects are mediated by translational or other posttranscriptional mechanisms. Indeed, posttranscriptional mechanisms have been implicated in the regulation of I to,f . 26 Therefore, further experiments in future studies are warranted to explore these issues.
Our results also suggest that other pathways are involved in control of I to,f gene expression. Although the predominant effects of NF-B activation on I to,f were linked to altered KChIP2 expression, NF-B also modulated Kv4.2 expression. In particular, Kv4.2 expression increased with chronic PE/Pro treatment and IKK␤, while being reduced by IB␣SA. These results establish that NF-B positively regulates Kv4.2 expression. However, NF-B inhibition did not prevent the PE/Pro-induced increases in Kv4.2 levels, suggesting that when ␣-ARs are stimulated, other pathways dominate in regulating Kv4.2 subunits. It is well established that calcineurin signaling strongly regulates Kv4.2 expression. 9 Therefore, we tested the hypothesis that the increases in Kv4.2 expression with ␣-AR stimulation are mediated by calcineurin. Inhibition of calcineurin with CAIN significantly decreased KChIP2 in both the presence and the absence of PE/Pro, while having no effect on Kv4.3 expression ( Figure 7 ). However, CAIN did reverse the increase in Kv4.2 expression caused by PE/Pro, albeit the decreased expression is much less than control. For the Kv4.2 data, a 2-way ANOVA analysis showed no interaction between PE/Pro and CAIN. These data are consistent with our previous studies 9 and support the conclusion that calcineurin signaling is not involved in mediating ␣-AR-induced changes of I to,f or its underlying molecular components, despite its ability to upregulate KChIP2 and Kv4.2 independently from ␣ 1 -AR activation. By contrast, Kv4.3 expression was unaffected by NF-B, establishing that Kv4.3 in not under the control of NF-B transcriptional activity.
Another interesting aspect of our studies was the finding that ␣and ␤-ARs differentially affect I to,f gene expression. Specifically, whereas ␤-AR and ␣-AR stimulation both decrease expression of KChIP2 and Kv4.3 levels, they have opposite effects on Kv4.2 expression. Because PE can mildly activate ␤-ARs, Pro was included in our studies to ensure selective ␣-AR stimulation. The ability of PE/Pro treatment to selectively activate ␣-ARs only was confirmed by using the ␣ 1 -AR blocker Pz, which prevented PE/Pro-induced changes in KChIP2 and Kv4.3 expression ( Figure 2 ). PE/Pro plus Pz did, however, cause small Kv4.2 reductions, similar to that seen with chronic Pro alone, which could originate from inverse agonism of ␤-ARs and the activation of ERK1/2 reported previously for Pro. 18, 27 It is tempting to speculate that ERK could mediate the reductions in Kv4.2 expression with Pro alone, because ERKs, as well as mitogen-activated protein kinases (MAPKs) in general, have been implicated in both transcriptional 16 and posttranslational regulation 26 of I to,f . In addition, many stimuli activating MAPK family proteins also activate NF-B. 28 The possible interactions between ERKs and MAPKs with NF-B in regulation of I to,f will clearly need further study.
In summary, our results identify a novel mechanism linking changes in I to,f and KChIP2 29 -31 to the alterations in ␣ 1 -AR stimulation, TNF␣ levels and NF-B signaling 32 observed in patients (and animal models) with cardiac hypertrophy and heart failure. Although we believe our conclusions in neonatal myocytes are applicable to adult myocardium given that NF-B activation and I to,f reductions are hallmarks of heart disease, additional studies are warranted to determine whether modulation of NF-B will be an effective treatment strategy in preventing the deleterious electric remodeling occurring in heart disease. 
